Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2023-10-18 Report Publication Anno…
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Invitation to presentation of third quarter results
Report Publication Announcement Classification · 98% confidence The document is extremely short (543 characters) and serves as an 'Invitation to presentation of third quarter results'. It announces the date (October 26th) and time for presenting the Q3 2023 results and provides a link to join the webcast. This is not the actual earnings release (ER) or the interim report (IR) itself, but rather an announcement about the upcoming presentation of those results. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement about the publication or presentation of results points towards a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Since it specifically announces the presentation of results, RPA is the most fitting category.
2023-10-18 English
Expanding product portfolio with turbidimetric Retinol-Binding Protein (RBP) immunoassay
Environmental & Social Information Classification · 99% confidence The document is a press release dated September 29, 2023, announcing the launch and availability of a new CE-marked diagnostic test (Gentian Retinol-Binding Protein Immunoassay). It details the product, market potential, and includes quotes from the CEO and contact information for sales and investors. This type of announcement, focusing on a new product launch or significant business development that is not a formal financial report (like 10-K or IR) or a transcript, best fits the category for general regulatory announcements or news releases that don't fit elsewhere. Since it is a specific announcement of a business event (product launch) and not a formal financial filing, it is classified as a Regulatory Filing (RNS) as the most appropriate general category, although 'Report Publication Announcement' (RPA) is sometimes used for product announcements, RNS is the designated fallback for miscellaneous regulatory/news announcements.
2023-09-29 English
Expanding product portfolio with turbidimetric Retinol-Binding Protein (RBP) immunoassay
Regulatory Filings Classification · 95% confidence The document is a press release dated September 29, 2023, announcing the launch and availability of a new CE-marked diagnostic test (Gentian Retinol-Binding Protein Immunoassay). It details the product's features, market potential, and strategic importance to the company. This type of announcement, focusing on a new product launch or significant operational update that is not a full financial report (like 10-K or IR) or a formal regulatory filing for a specific event (like AGM or DVA), fits best under the general category for corporate news releases that don't fit other specific codes. Since it is a general announcement of a business development/product launch, and not a formal earnings release (ER) or a specific capital/financing update (CAP), the most appropriate general category is Regulatory Filings (RNS) as a catch-all for corporate news, although it strongly resembles an Earnings Release (ER) in format, it lacks the required financial metrics summary typical of an ER. Given the context of a product launch announcement, RNS is the safest fallback if a more specific 'Product Launch' code is unavailable. However, looking closely at the definitions, this is a direct announcement of a business event/product availability, which often falls under general regulatory news dissemination. Since it is not a financial report, a call transcript, or a management discussion, RNS (Regulatory Filings/General Announcement) is the best fit among the provided options for a non-financial, non-event-specific corporate update.
2023-09-29 English
Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document text is titled 'KRT-1500 Skjema for melding om transaksjoner utført av personer med ledelsesansvar ( primærinnsidere ) og deres nærstående'. This explicitly describes a report detailing share transactions by primary insiders (executives/directors). The content details the insider's name (NJAAL KIND), role (CFO), the instrument (Aksje/Share), transaction type (Kjøp/Buy), volume (5,000), and price (43.4 NOK) on a specific date (29.08.2023). This perfectly matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2023-08-29 Norwegian
Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled 'Mandatory notification of trade' and explicitly states that a 'primary insider Njaal Kind (CFO)' purchased shares. This directly corresponds to the definition of Director's Dealing (insider trades) as per the provided categories. The filing type code for Director's Dealing is DIRS.
2023-08-29 English
Second quarter 2023 report
Investor Presentation Classification · 98% confidence The document is explicitly titled 'Q2 23 Presentation' and contains slides detailing financial highlights for the second quarter of 2023 ('2Q23 financials and key milestones Highlights'). It includes product portfolios, market analysis, growth figures, and a 'Financial review' section. This structure is characteristic of an Investor Presentation (IP) used to communicate performance and strategy to investors, often following an earnings release. It is not a full Annual Report (10-K), a standalone Audit Report (AR), or just an Earnings Release (ER) which typically contains only the key numbers. The presence of detailed slides and forward-looking statements strongly points to an Investor Presentation.
2023-08-24 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.